The impact of exercise on statin-associated skeletal muscle myopathy

Hae R. Chung, Mayand Vakil, Michael Munroe, Alay Parikh, Benjamin M. Meador, Pei T. Wu, Jin H. Jeong, Jeffrey A. Woods, Kenneth R. Wilund, Marni D. Boppart

Research output: Contribution to journalArticle

Abstract

HMG-CoA reductase inhibitors (statins) are the most effective pharmacological means of reducing cardiovascular disease risk. The most common side effect of statin use is skeletal muscle myopathy, which may be exacerbated by exercise. Hypercholesterolemia and training status are factors that are rarely considered in the progression of myopathy. The purpose of this study was to determine the extent to which acute and chronic exercise can influence statin-induced myopathy in hypercholesterolemic (ApoE -/- ) mice. Mice either received daily injections of saline or simvastatin (20 mg/kg) while: 1) remaining sedentary (Sed), 2) engaging in daily exercise for two weeks (novel, Nov), or 3) engaging in daily exercise for two weeks after a brief period of training (accustomed, Acct) (2x3 design, n = 60). Cholesterol, activity, strength, and indices of myofiber damage and atrophy were assessed. Running wheel activity declined in both exercise groups receiving statins (statin x time interaction, p<0.05). Cholesterol, grip strength, and maximal isometric force were significantly lower in all groups following statin treatment (statin main effect, p<0.05). Mitochondrial content and myofiber size were increased and 4-HNE was decreased by exercise (statin x exercise interaction, p<0.05), and these beneficial effects were abrogated by statin treatment. Exercise (Acct and Nov) increased atrogin-1 mRNA in combination with statin treatment, yet enhanced fiber damage or atrophy was not observed. The results from this study suggest that exercise (Nov, Acct) does not exacerbate statin-induced myopathy in ApoE-/- mice, yet statin treatment reduces activity in a manner that prevents muscle from mounting a beneficial adaptive response to training.

Original languageEnglish (US)
Article numbere0168065
JournalPloS one
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
muscular diseases
Muscular Diseases
Muscle
skeletal muscle
Skeletal Muscle
exercise
atrophy
mice
Apolipoproteins E
cholesterol
Atrophy
hypercholesterolemia
wheels
Cholesterol
cardiovascular diseases
Simvastatin
adverse effects
Hand Strength
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chung, H. R., Vakil, M., Munroe, M., Parikh, A., Meador, B. M., Wu, P. T., ... Boppart, M. D. (2016). The impact of exercise on statin-associated skeletal muscle myopathy. PloS one, 11(12), [e0168065]. https://doi.org/10.1371/journal.pone.0168065

The impact of exercise on statin-associated skeletal muscle myopathy. / Chung, Hae R.; Vakil, Mayand; Munroe, Michael; Parikh, Alay; Meador, Benjamin M.; Wu, Pei T.; Jeong, Jin H.; Woods, Jeffrey A.; Wilund, Kenneth R.; Boppart, Marni D.

In: PloS one, Vol. 11, No. 12, e0168065, 01.12.2016.

Research output: Contribution to journalArticle

Chung, HR, Vakil, M, Munroe, M, Parikh, A, Meador, BM, Wu, PT, Jeong, JH, Woods, JA, Wilund, KR & Boppart, MD 2016, 'The impact of exercise on statin-associated skeletal muscle myopathy', PloS one, vol. 11, no. 12, e0168065. https://doi.org/10.1371/journal.pone.0168065
Chung HR, Vakil M, Munroe M, Parikh A, Meador BM, Wu PT et al. The impact of exercise on statin-associated skeletal muscle myopathy. PloS one. 2016 Dec 1;11(12). e0168065. https://doi.org/10.1371/journal.pone.0168065
Chung, Hae R. ; Vakil, Mayand ; Munroe, Michael ; Parikh, Alay ; Meador, Benjamin M. ; Wu, Pei T. ; Jeong, Jin H. ; Woods, Jeffrey A. ; Wilund, Kenneth R. ; Boppart, Marni D. / The impact of exercise on statin-associated skeletal muscle myopathy. In: PloS one. 2016 ; Vol. 11, No. 12.
@article{94796c0371d24e879c9cc4e323cb5b06,
title = "The impact of exercise on statin-associated skeletal muscle myopathy",
abstract = "HMG-CoA reductase inhibitors (statins) are the most effective pharmacological means of reducing cardiovascular disease risk. The most common side effect of statin use is skeletal muscle myopathy, which may be exacerbated by exercise. Hypercholesterolemia and training status are factors that are rarely considered in the progression of myopathy. The purpose of this study was to determine the extent to which acute and chronic exercise can influence statin-induced myopathy in hypercholesterolemic (ApoE -/- ) mice. Mice either received daily injections of saline or simvastatin (20 mg/kg) while: 1) remaining sedentary (Sed), 2) engaging in daily exercise for two weeks (novel, Nov), or 3) engaging in daily exercise for two weeks after a brief period of training (accustomed, Acct) (2x3 design, n = 60). Cholesterol, activity, strength, and indices of myofiber damage and atrophy were assessed. Running wheel activity declined in both exercise groups receiving statins (statin x time interaction, p<0.05). Cholesterol, grip strength, and maximal isometric force were significantly lower in all groups following statin treatment (statin main effect, p<0.05). Mitochondrial content and myofiber size were increased and 4-HNE was decreased by exercise (statin x exercise interaction, p<0.05), and these beneficial effects were abrogated by statin treatment. Exercise (Acct and Nov) increased atrogin-1 mRNA in combination with statin treatment, yet enhanced fiber damage or atrophy was not observed. The results from this study suggest that exercise (Nov, Acct) does not exacerbate statin-induced myopathy in ApoE-/- mice, yet statin treatment reduces activity in a manner that prevents muscle from mounting a beneficial adaptive response to training.",
author = "Chung, {Hae R.} and Mayand Vakil and Michael Munroe and Alay Parikh and Meador, {Benjamin M.} and Wu, {Pei T.} and Jeong, {Jin H.} and Woods, {Jeffrey A.} and Wilund, {Kenneth R.} and Boppart, {Marni D.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0168065",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - The impact of exercise on statin-associated skeletal muscle myopathy

AU - Chung, Hae R.

AU - Vakil, Mayand

AU - Munroe, Michael

AU - Parikh, Alay

AU - Meador, Benjamin M.

AU - Wu, Pei T.

AU - Jeong, Jin H.

AU - Woods, Jeffrey A.

AU - Wilund, Kenneth R.

AU - Boppart, Marni D.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - HMG-CoA reductase inhibitors (statins) are the most effective pharmacological means of reducing cardiovascular disease risk. The most common side effect of statin use is skeletal muscle myopathy, which may be exacerbated by exercise. Hypercholesterolemia and training status are factors that are rarely considered in the progression of myopathy. The purpose of this study was to determine the extent to which acute and chronic exercise can influence statin-induced myopathy in hypercholesterolemic (ApoE -/- ) mice. Mice either received daily injections of saline or simvastatin (20 mg/kg) while: 1) remaining sedentary (Sed), 2) engaging in daily exercise for two weeks (novel, Nov), or 3) engaging in daily exercise for two weeks after a brief period of training (accustomed, Acct) (2x3 design, n = 60). Cholesterol, activity, strength, and indices of myofiber damage and atrophy were assessed. Running wheel activity declined in both exercise groups receiving statins (statin x time interaction, p<0.05). Cholesterol, grip strength, and maximal isometric force were significantly lower in all groups following statin treatment (statin main effect, p<0.05). Mitochondrial content and myofiber size were increased and 4-HNE was decreased by exercise (statin x exercise interaction, p<0.05), and these beneficial effects were abrogated by statin treatment. Exercise (Acct and Nov) increased atrogin-1 mRNA in combination with statin treatment, yet enhanced fiber damage or atrophy was not observed. The results from this study suggest that exercise (Nov, Acct) does not exacerbate statin-induced myopathy in ApoE-/- mice, yet statin treatment reduces activity in a manner that prevents muscle from mounting a beneficial adaptive response to training.

AB - HMG-CoA reductase inhibitors (statins) are the most effective pharmacological means of reducing cardiovascular disease risk. The most common side effect of statin use is skeletal muscle myopathy, which may be exacerbated by exercise. Hypercholesterolemia and training status are factors that are rarely considered in the progression of myopathy. The purpose of this study was to determine the extent to which acute and chronic exercise can influence statin-induced myopathy in hypercholesterolemic (ApoE -/- ) mice. Mice either received daily injections of saline or simvastatin (20 mg/kg) while: 1) remaining sedentary (Sed), 2) engaging in daily exercise for two weeks (novel, Nov), or 3) engaging in daily exercise for two weeks after a brief period of training (accustomed, Acct) (2x3 design, n = 60). Cholesterol, activity, strength, and indices of myofiber damage and atrophy were assessed. Running wheel activity declined in both exercise groups receiving statins (statin x time interaction, p<0.05). Cholesterol, grip strength, and maximal isometric force were significantly lower in all groups following statin treatment (statin main effect, p<0.05). Mitochondrial content and myofiber size were increased and 4-HNE was decreased by exercise (statin x exercise interaction, p<0.05), and these beneficial effects were abrogated by statin treatment. Exercise (Acct and Nov) increased atrogin-1 mRNA in combination with statin treatment, yet enhanced fiber damage or atrophy was not observed. The results from this study suggest that exercise (Nov, Acct) does not exacerbate statin-induced myopathy in ApoE-/- mice, yet statin treatment reduces activity in a manner that prevents muscle from mounting a beneficial adaptive response to training.

UR - http://www.scopus.com/inward/record.url?scp=85006041915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006041915&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0168065

DO - 10.1371/journal.pone.0168065

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0168065

ER -